Spatially Resolving the Secretome within the Mycelium of the Cell Factory <i>Aspergillus niger</i> per Pauline Krijgsheld (1973917)

Spatially Resolving the Secretome within the Mycelium of the Cell Factory <i>Aspergillus niger</i> per Pauline Krijgsheld (1973917)

Spatially Resolving the Secretome within the Mycelium of the Cell Factory <i>Aspergillus niger</i> per Pauline Krijgsheld (1973917)

Data Sheet 2_The Learn Together programme (part A): co-designing an approach to support patient and family involvement and engagement in patient safety incident investigations.pdf per Jane K. O’Hara (8828342)

Matèries:

Data Sheet 3_The Learn Together programme (part A): co-designing an approach to support patient and family involvement and engagement in patient safety incident investigations.pdf per Jane K. O’Hara (8828342)

Matèries:

Data Sheet 1_The Learn Together programme (part A): co-designing an approach to support patient and family involvement and engagement in patient safety incident investigations.pdf per Jane K. O’Hara (8828342)

Matèries:

Time to self-harm event after admission during most recent incarceration. per Hygiea Casiano (2189752)

Demographic correlates of self-harm while in youth custody during most recent incarceration. per Hygiea Casiano (2189752)

Examples of terms used in the academic literature to describe practice encounters not involving in-person contact. per Kathleen Leslie (15374710)

Reasons and patterns of self-harm patients. per Willie Njoroge (20623714)

Matèries:

Self-harm patients’ spiritual history. per Willie Njoroge (20623714)

Matèries:

Development of immune factors over visits in the AAF and AAF-syn treatment group as (A) scores and (B) loadings. per Diana M. Hendrickx (1507435)

Results of comparing visits within allergy groups using linear mixed models and post hoc analysis. per Diana M. Hendrickx (1507435)

Results of comparing allergy groups within visits using linear mixed models and post hoc analysis. per Diana M. Hendrickx (1507435)

Development of immune factors over visits in the AAF-syn treatment group as (A) scores and (B) loadings when using the AAF treatment group as a reference. per Diana M. Hendrickx (1507435)

Results of comparing treatment groups within visits using linear mixed models and post hoc analysis. per Diana M. Hendrickx (1507435)

Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within allergy groups as determined by linear mixed models and post hoc analysis. per Diana M. Hendrickx (1507435)

Results of comparing visits within treatment groups using linear mixed models and post hoc analysis. per Diana M. Hendrickx (1507435)

Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within treatment groups as determined by linear mixed models and post hoc analysis. per Diana M. Hendrickx (1507435)

KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between treatment groups within visits as determ... per Diana M. Hendrickx (1507435)